Pushkal Garg, CMO & EVP Development & Med Affairs at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 5,270 shares at $252.50 ($1.3M) on 2025-02-14, disclosed to the SEC on 2025-02-18.
Scheduled sale ($1.3M) by CMO & EVP Development & Med Affairs under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $252.50 | 349 | $88K | 6.6% |
| 2 | $252.50 | 349 | $88K | 6.6% |
| 3 | $253.37 | 386 | $98K | 7.3% |
| 4 | $253.37 | 386 | $98K | 7.3% |
| 5 | $254.35 | 258 | $66K | 4.9% |
| 6 | $254.35 | 258 |
| $66K |
| 4.9% |
| 7 | $255.56 | 110 | $28K | 2.1% |
| 8 | $256.29 | 126 | $32K | 2.4% |
| 9 | $257.51 | 60 | $15K | 1.2% |
| 10 | $258.07 | 77 | $20K | 1.5% |
| 11 | $259.72 | 27 | $7K | 0.5% |
| 12 | $260.57 | 49 | $13K | 1.0% |
| 13 | $261.45 | 60 | $16K | 1.2% |
| 14 | $263.33 | 27 | $7K | 0.5% |
| 15 | $264.87 | 32 | $8K | 0.6% |
| 16 | $250.11 | 862 | $216K | 16.2% |
| 17 | $250.11 | 862 | $216K | 16.2% |
| 18 | $250.73 | 306 | $77K | 5.8% |
| 19 | $250.73 | 306 | $77K | 5.8% |
| 20 | $251.60 | 110 | $28K | 2.1% |
| 21 | $256.05 | 83 | $21K | 1.6% |
| 22 | $257.99 | 107 | $28K | 2.1% |
| 23 | $259.10 | 80 | $21K | 1.6% |
| Total | $252.71 avg | 5,270 | $1.3M | 100% |
| Filing → |
| ALNY | SELL | 2026-03-02 | $1.5M | — | Filing → |
| ALNY | SELL | 2026-02-17 | $695K | — | Filing → |
| ALNY | SELL | 2026-01-14 | $548K | — | Filing → |